Do The IMPROVE-IT Results Offer Promise For Anacetrapib, Another Merck Heart Drug?

Despite the fact that anacetrapib lowers LDL at least as well as Vytorin did in IMPROVE-IT, the FDA would never approve anacetrapib based solely on LDL lowering. This is a new experimental agent and the results of REVEAL are needed before the FDA can act. This is not an unreasonable position. It will be interesting to see how the FDA will respond to other experimental LDL lowering agents. Will the results of outcome studies be needed for those drugs as well?
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news